These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33105142)

  • 1. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
    Díaz Y; Ramos-Suzarte M; Martín Y; Calderón NA; Santiago W; Viñet O; La O Y; Oyarzábal JPA; Pérez Y; Lorenzo G; Cepeda M; Saavedra D; Mazorra Z; Estevez D; Lorenzo-Luaces P; Valenzuela C; Caballero A; Leon K; Crombet T; Hidalgo CJ
    Gerontology; 2020; 66(6):553-561. PubMed ID: 33105142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.
    Saavedra D; Añé-Kourí AL; Sánchez N; Filgueira LM; Betancourt J; Herrera C; Manso L; Chávez E; Caballero A; Hidalgo C; Lorenzo G; Cepeda M; Valenzuela C; Ramos M; León K; Mazorra Z; Crombet T
    Immun Ageing; 2020 Nov; 17(1):34. PubMed ID: 33292350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study.
    Gore V; Kshirsagar DP; Bhat SM; Khatib KI; Mansukhani B
    J Assoc Physicians India; 2021 Feb; 69(2):13-18. PubMed ID: 33527804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
    Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A
    Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
    Kumar S; De Souza R; Nadkar M; Guleria R; Trikha A; Joshi SR; Loganathan S; Vaidyanathan S; Marwah A; Athalye SN
    Expert Opin Biol Ther; 2021 May; 21(5):675-686. PubMed ID: 33835886
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
    Hernández P; Moreno E; Aira LE; Rodríguez PC
    Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
    Loganathan S; Athalye SN; Joshi SR
    Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
    Rodríguez PC; Prada DM; Moreno E; Aira LE; Molinero C; López AM; Gómez JA; Hernández IM; Martínez JP; Reyes Y; Milera JM; Hernández MV; Torres R; Avila Y; Barrese Y; Viada C; Montero E; Hernández P
    Clin Exp Immunol; 2018 Feb; 191(2):229-239. PubMed ID: 28963724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.
    Caballero A; Filgueira LM; Betancourt J; Sánchez N; Hidalgo C; Ramírez A; Martinez A; Despaigne RE; Escalona A; Diaz H; Meriño E; Ortega LM; Castillo U; Ramos M; Saavedra D; García Y; Lorenzo G; Cepeda M; Arencibia M; Cabrera L; Domecq M; Estévez D; Valenzuela C; Lorenzo P; Sánchez L; Mazorra Z; León K; Crombet T
    Clin Transl Immunology; 2020; 9(11):e1218. PubMed ID: 33304584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program.
    Falcón Lincheta L; Saumell Nápoles Y; Gray Lovio OR; Viqueira Fuentesfría AM; Pérez Alonso T; Batista Romagoza M; Urquiza Rodríguez A; Mantecón Fernández B; Bautista Jerez HA; Fernández de Armas D; Martínez Matute ES; León García Y; Oramas Fernández DK; Marrero Chavez Y; Fernandez Lorente A; Valls Hung AR; Lorenzo-Luaces P; Valenzuela Silva C; Moreno E; Hernández-Casaña P
    Int Immunopharmacol; 2024 Jun; 134():112225. PubMed ID: 38759368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center.
    Aguilar TL; Gorry C
    MEDICC Rev; 2021 Apr; 23(2):12. PubMed ID: 33974610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Kr R; Rathod C; Darnule R; Loganathan S; Deodhar S; A R; Marwah A; Chaudhari NM; Thakur BK; Vaidyanathan S; Athalye SN
    Expert Opin Biol Ther; 2023 May; 23(5):443-454. PubMed ID: 37073744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
    Atal S; Fatima Z; Balakrishnan S
    BioDrugs; 2020 Dec; 34(6):705-711. PubMed ID: 33048300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
    Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
    J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.
    Zuccon W; Comassi P; Adriani L; Bergamaschini G; Bertin E; Borromeo R; Corti S; De Petri F; Dolci F; Galmozzi A; Gigliotti A; Gualdoni L; Guerra C; Khosthiova A; Leati G; Lupi G; Moscato P; Perotti V; Piantelli M; Ruini A; Sportelli S; Susca M; Troiano C; Benelli G; Buscarini E; Canetta C; Merli G; Scartabellati A; Melilli B S C G; Sfogliarini R; Pellegatta G; Viganò G
    Am J Emerg Med; 2021 Jul; 45():156-161. PubMed ID: 33046317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.